Recombinant monoclonal antibody to TRAIL-R2. Lexatumumab (also known as ETR2-ST01) is an experimental agonistic human monoclonal antibody against TRAIL-R2 (DR5, APO-2) undergoing clinical trials for the treatment of cancer.
Figure 1 Cleaved caspase 8 was associated with DR4 or DR5 in relation to mapatumumab or lexatumumab sensitivity.
Immunoprecipitation assays of mapatumumab (Mapa) or lexatumumab (Lexa) were performed in LP1, MDN, NCI-H929 cells. Cells (20 x 106) were incubated with or without (control) 10ug/ml of mapatumumab (45min) or lexatumumab (90 min) at 37°C in RPMI1640 containing 5% FCS. For NCIH929, cells were pretreated 2h with 2.5uM nutlin3a (N) before addition of lexatumumab. The lysates were immunoprecipitated with a mix of proteins A and G (2 mg of lysate proteins were immunoprecipitated in each assay). For untreated cells, IP was performed after addition of mapatumumab or lexatumumab to the lysates. The immunoprecipitates were analyzed for the presence of the indicated proteins by immunoblot analysis. Input: lysates of untreated or treated cells, Ct IP: immunoprecipitation of control lysates (untreated cells), IP: immunoprecipitation of lysates obtained from cells treated with mapatumumab or lexatumumab. * indicates heavy chain of mapatumumab or lexatumumab.
Surget, S., Chiron, D., Gomez-Bougie, P., Descamps, G., Ménoret, E., Bataille, R., ... & Pellat-Deceunynck, C. (2012). Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells. Cancer research, canres-0487.
Figure 2 TGFβ1 inhibits apoptotic signaling of TRAIL-R1.
Cells were treated for 24 h with Mapatumumab (10μg/ml, Mapa), Lexatumumab (10μg/ml, Lexa), with or without pre-incubation with TGFβ1 (10 ng/ml for 72 h). Cell death was determined by PI-staining followed byflow cytometric analysis. (A) or by measurements of ATP content using the commercial CellTiter-Glo Luminescent Cell Viability Assay (B). Induction ratio shown in (A) (Mapa or Lexa treatment/respective control) is indicated below the histograms as fold of induction. Data depicted in A) and B) are shown as mean ± SEM of three independent experiments. *pb0.05, n.s. non-significant. (C) Cells were treated for 24 h with Mapa (10μg/ml), Lexa (10μg/ml), or with TRAIL (50 ng/ml) with or without pre-incubation with TGFβ1 (10 ng/ml for 72 h). Analysis of the apoptotic signaling cascade was performed on whole cell lysates by Western blot using antibodies against caspase 8, Bid and caspase 3. For the control of the gel loading,β-actin levels were determined in parallel.
Radke, D. I., Ungefroren, H., Helm, O., Voigt, S., Alp, G., Braun, H., ... & Kalthoff, H. (2016). Negative control of TRAIL-R1 signaling by transforming growth factor β1 in pancreatic tumor cells involves Smad-dependent down regulation of TRAIL-R1. Cellular signalling, 28(11), 1652-1662.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Afuco™ Anti-TNFRSF10B ADCC Recombinant Antibody (Lexatumumab), ADCC EnhancedThis product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to TRAIL-R2. Lexatumumab (also known as ETR2-ST01) is an experimental agonistic human monoclonal antibody against TRAIL-R2 (DR5, APO-2) undergoing clinical trials for the treatment of cancer.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-1172z | Mouse Anti-TNFRSF10B Recombinant Antibody (clone 40C9) | FC, ICC, IHC, IP, FuncS | Mouse IgG1 |
PABW-057 | Human Anti-TNFRSF10B Recombinant Antibody (clone YSd1) | ELISA | Human IgG |
FN-235CQ | Hamster Anti-Tnfrsf10b Recombinant Antibody (clone MD5-1) | FC, FuncS | Hamster IgG |
HPAB-M0231-YC | Human Anti-TNFRSF10B Recombinant Antibody (clone TR2-3) | ELISA, WB | Human IgG |
HPAB-0941-FY | Human Anti-TNFRSF10B Recombinant Antibody (HPAB-0941-FY) | ELISA | Human IgG1 |
CAT | Product Name | Application | Type |
---|---|---|---|
NABL-052 | Recombinant Anti-human TNFRSF10B VHH Single Domain Antibody | WB, ELISA, IHC, FC, FuncS | Llama VHH |
HPAB-0703-YJ-VHH | Camelid Anti-TNFRSF10B Recombinant Single Domain Antibody (3-DR5) | ELISA, Apop | Camelid VHH |
HPAB-0704-YJ-VHH | Camelid Anti-TNFRSF10B Recombinant Single Domain Antibody (6-DR5) | ELISA | Camelid VHH |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-196 | Anti-Human TRAIL-R2 Recombinant Antibody (Tigatuzumab) | IF, IP, Neut, FuncS, ELISA, FC, ICC | IgG1 |
TAB-250MZ | Human Anti-TNFRSF10B Recombinant Antibody (TAB-250MZ) | FuncS | Humanized IgG |
TAB-251MZ | Human Anti-TNFRSF10B Recombinant Antibody (TAB-251MZ) | FuncS | Humanized IgG |
TAB-250MZ-S(P) | Human Anti-TNFRSF10B Recombinant Antibody; scFv Fragment (TAB-250MZ-S(P)) | FC, ELISA | Humanized scFv |
TAB-251MZ-S(P) | Human Anti-TNFRSF10B Recombinant Antibody; scFv Fragment (TAB-251MZ-S(P)) | FC, ELISA | Humanized scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-180 | Anti-Human DR5 Recombinant Antibody (Drozitumab) | FuncS, IF, Neut, ELISA, FC, IP, ICC | IgG1 - lambda |
TAB-253MZ | Anti-Human TNFRSF10B Recombinant Antibody (AU11) | ELISA, FuncS | Human antibody |
TAB-254MZ | Anti-Human TNFRSF10B Recombinant Antibody (AU12) | ELISA, FuncS | Human antibody |
TAB-253MZ-F(E) | Anti-Human TNFRSF10B Recombinant Antibody Fab Fragment (AU11) | FC, ELISA | Human antibody |
TAB-254MZ-F(E) | Anti-Human TNFRSF10B Recombinant Antibody Fab Fragment (AU12) | FC, ELISA | Human antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-625CL | Human Anti-TNFRSF10B Recombinant Antibody (TAB-625CL) | ELISA | Single Domain Antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
PSBC-123 | Human Anti-TNFRSF10B Recombinant Antibody (clone BDF1); scFv Fragment | ELISA | Human scFv |
HPAB-M0231-YC-S(P) | Human Anti-TNFRSF10B Recombinant Antibody (clone TR2-3); scFv Fragment | ELISA, WB | Human scFv |
HPAB-N0268-YC-S(P) | Human Anti-TNFRSF10B Recombinant Antibody; scFv Fragment (HPAB-N0268-YC-S(P)) | FC, Inhib | Human scFv |
HPAB-2047-FY-S(P) | Human Anti-TNFRSF10B Recombinant Antibody; scFv Fragment (HPAB-2047-FY-S(P)) | IA | Human scFv |
HPAB-0672YY-S(P) | Human Anti-TNFRSF10B Recombinant Antibody; scFv Fragment (HPAB-0672YY-S(P)) | ELISA, FuncS | Human scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-247MZ-S(P) | Mouse Anti-TNFRSF10B Recombinant Antibody; scFv Fragment (TAB-247MZ-S(P)) | ELISA, WB | Mouse scFv |
TAB-247MZ-F(E) | Mouse Anti-TNFRSF10B Recombinant Antibody; Fab Fragment (TAB-247MZ-F(E)) | ELISA, WB | Mouse Fab |
TAB-248MZ-F(E) | Mouse Anti-TNFRSF10B Recombinant Antibody; Fab Fragment (TAB-248MZ-F(E)) | FC, ELISA | Mouse Fab |
TAB-249MZ-F(E) | Mouse Anti-TNFRSF10B Recombinant Antibody; Fab Fragment (TAB-249MZ-F(E)) | FC, ELISA | Mouse Fab |
TAB-252MZ-F(E) | Anti-Human TNFRSF10B Recombinant Antibody Fab Fragment | ELISA |
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-3604 | Rabbit Anti-TNFRSF10B Recombinant Antibody (clone DS3604AB), PE | FC, WB | Rabbit IgG |
MOR-3605 | Rabbit Anti-Tnfrsf10b Recombinant Antibody (clone DS3605AB) | ELISA | Rabbit IgG |
MOR-4468 | Rabbit Anti-Tnfrsf10b Recombinant Antibody (clone SI562DS) | ELISA | Rabbit IgG |
MOR-4469 | Rabbit Anti-TNFRSF10B Recombinant Antibody (clone SI563DS) | ELISA, FC | Rabbit IgG |
MOR-4473 | Rabbit Anti-TNFRSF10B Recombinant Antibody (clone SI567DS) | FC | Rabbit IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-104LC | Human Anti-TNFRSF10B Recombinant Antibody (MOB-104LC) | FuncS | Chimeric (mouse/human) IgG1, κ |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0303-YC-F(E) | Human Anti-TNFRSF10B Recombinant Antibody; Fab Fragment (HPAB-0303-YC-F(E)) | ELISA, FuncS | Humanized Fab |
HPAB-0304-YC-F(E) | Human Anti-TNFRSF10B Recombinant Antibody; Fab Fragment (HPAB-0304-YC-F(E)) | FuncS | Human Fab |
HPAB-N0268-YC-F(E) | Human Anti-TNFRSF10B Recombinant Antibody; Fab Fragment (HPAB-N0268-YC-F(E)) | FC, Inhib | Humanized Fab |
HPAB-0941-FY-S(P) | Human Anti-TNFRSF10B Recombinant Antibody; scFv Fragment (HPAB-0941-FY-S(P)) | ELISA | Human scFv |
HPAB-0416-YJ-F(E) | Mouse Anti-TNFRSF10B Recombinant Antibody; Fab Fragment (HPAB-0416-YJ-F(E)) | ELISA, FuncS | Mouse Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-196 | Afuco™ Anti-TNFRSF10B ADCC Recombinant Antibody (Tigatuzumab), ADCC Enhanced | IF, IP, Neut, FuncS, ELISA, FC | ADCC enhanced antibody |
AFC-TAB-203 | Afuco™ Anti-TNFRSF10B Recombinant Antibody (AFC-TAB-203), ADCC Enhanced | ELISA, IP, FC, FuncS, Neut, IF | Human IgG1, κ |
AFC-TAB-180 | Afuco™ Anti-TNFRSF10B ADCC Recombinant Antibody (Drozitumab), ADCC Enhanced | FuncS, IF, Neut, ELISA, FC, IP | ADCC enhanced antibody |
AFC-TAB-195 | Afuco™ Anti-TNFRSF10B ADCC Recombinant Antibody (Lexatumumab), ADCC Enhanced | ELISA, IP, FC, FuncS, Neut, IF | ADCC enhanced antibody |
There are currently no Customer reviews or questions for TAB-195. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.